• 4-Alkylated Silver–N-Heterocyclic Carbene (NHC) Complexes with Cytotoxic Effects in Leukemia Cells 

      Sandtorv, Alexander Harald; Leitch, Calum; Bedringaas, Siv Lise; Gjertsen, Bjørn Tore; Bjørsvik, Hans-Rene (Peer reviewed; Journal article, 2015-08-06)
      Computational chemistry has shown that backbone-alkylated imidazoles ought to be efficient ligands for transition metal catalysts with improved carbene-to-metal donation. In this work, such alkylated imidazoles were ...
    • Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia 

      Leitch, Calum; Osdal, Tereza; Andresen, Vibeke; Molland, Maren Kristine Butler; Kristiansen, Silje Elisabeth; Nguyen, Nhi Xuan; Bruserud, Øystein; Gjertsen, Bjørn Tore; McCormack, Emmet (Peer reviewed; Journal article, 2016)
      Palliative care in acute myeloid leukaemia (AML) is inadequate. For elderly patients, unfit for intensive chemotherapy, median survival is 2–3 months. As such, there is urgent demand for low-toxic palliative alternatives. ...
    • Identification and development of small molecule therapies for the treatment of acute myeloid leukaemia 

      Leitch, Calum (Doctoral thesis, 2022-02-11)
      Acute myeloid leukaemia (AML) is a cancer of the bone marrow in which immature myeloid cells exhibit uncontrolled proliferation and failure to differentiate. The global 5-year overall survival rate for AML ranges between ...
    • Repurposing chlorpromazine for anti-leukaemic therapy by nanoparticle encapsulation 

      Gundersen, Edvin Tang; Førde, Jan-Lukas; Tislevoll, Benedicte Sjo; Leitch, Calum; Barratt, Gillian; Gjertsen, Bjørn Tore; Herfindal, Lars (Journal article; Peer reviewed, 2022)
      Treatment of acute myeloid leukaemia (AML) relies on decades-old drugs, and while recent years have seen some breakthroughs, AML is still characterised by poor prognosis and survival rate. Drug repurposing can expedite the ...